Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water

Even a pandemic can’t slow Seattle Genetics’ new bladder cancer treatment Padcev down—and analysts are jacking up their sales estimates for the drug as a result.

In its first quarter on the market after a mid-December FDA approval, the therapy “blew out expectations … exceeding consensus estimates" by four- to fivefold with $34.5 million in sales, J.P. Morgan analyst Cory Kasimov wrote in a note to clients.